化疗在非转移性鼻咽癌中的当前作用
Current Role of Chemotherapy in Nonmetastatic Nasopharyngeal Cancer.
作者信息
Bhattacharyya Tapesh, Babu Geethu, Kainickal Cessal Thommachan
机构信息
Division of Radiation Oncology, Tata Medical Center, Kolkata, India.
Division of Radiation Oncology, Regional Cancer Centre, Trivandrum, India.
出版信息
J Oncol. 2018 Oct 1;2018:3725837. doi: 10.1155/2018/3725837. eCollection 2018.
Abstract
Nasopharyngeal carcinoma is highly radio- and chemosensitive tumor with its unique clinical and biological behavior. Treatment of stage I disease is radical radiotherapy alone. For stage II disease treatment is radiotherapy with or without chemotherapy. The standard of care for locally advanced nasopharyngeal cancer (stages III-IVB) is concurrent chemoradiation. Optimum timing and sequence of chemotherapy are not yet well-defined. The role of adjuvant and induction chemotherapy is debatable. Here we are going to highlight the role of chemotherapy in nasopharyngeal carcinoma, its benefit, and controversies regarding timing and sequences.
摘要
鼻咽癌是一种对放疗和化疗高度敏感的肿瘤，具有独特的临床和生物学行为。I期疾病的治疗是单纯根治性放疗。II期疾病的治疗是放疗加或不加化疗。局部晚期鼻咽癌（III-IVB期）的标准治疗是同步放化疗。化疗的最佳时机和顺序尚未明确界定。辅助化疗和诱导化疗的作用存在争议。在此，我们将重点阐述化疗在鼻咽癌中的作用、其益处以及关于时机和顺序的争议。
相似文献
1
Current Role of Chemotherapy in Nonmetastatic Nasopharyngeal Cancer.化疗在非转移性鼻咽癌中的当前作用
J Oncol. 2018 Oct 1;2018:3725837. doi: 10.1155/2018/3725837. eCollection 2018.
2
Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.诱导多西他赛、铂类和氟尿嘧啶化疗对接受同步放化疗的III期或IVA/B期鼻咽癌患者的影响：两项平行的2期临床试验的最终结果
Cancer. 2017 Jun 15;123(12):2258-2267. doi: 10.1002/cncr.30566. Epub 2017 Feb 13.
3
Management of Chemotherapy for Stage II Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era: A Review.调强放射治疗时代II期鼻咽癌的化疗管理：综述
Cancer Manag Res. 2020 Feb 10;12:957-963. doi: 10.2147/CMAR.S239729. eCollection 2020.
4
Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma.局部晚期鼻咽癌先行新辅助化疗，随后进行同步放化疗。
Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):508-13. doi: 10.1016/j.ijrobp.2004.09.050.
5
Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: interim results from 2 prospective phase 2 clinical trials.新辅助化疗后同期放化疗治疗局部晚期鼻咽癌：2 项前瞻性 2 期临床试验的中期结果。
Cancer. 2013 Dec 1;119(23):4111-8. doi: 10.1002/cncr.28324. Epub 2013 Aug 27.
6
Advances in nasopharyngeal carcinoma.鼻咽癌的进展
Curr Opin Oncol. 2005 May;17(3):225-30. doi: 10.1097/01.cco.0000156197.29872.8e.
7
Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy.辅助化疗增强局部晚期淋巴结阳性鼻咽癌的局部控制
Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):261-71. doi: 10.1016/s0360-3016(98)00383-6.
8
IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.调强适形放疗联合同步化疗加辅助化疗与调强适形放疗联合单纯同步化疗治疗鼻咽癌患者的比较
Oncotarget. 2017 Jun 13;8(24):39683-39694. doi: 10.18632/oncotarget.14799.
9
Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.新辅助化疗后序贯同步放化疗治疗局部晚期鼻咽癌。
Chin J Cancer. 2010 May;29(5):551-5. doi: 10.5732/cjc.009.10518.
10
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma.NPC-0501试验的初步结果，该试验评估了局部晚期鼻咽癌患者从同步辅助放化疗改为诱导-同步放化疗、从氟尿嘧啶改为卡培他滨以及从常规放疗分割改为加速放疗分割后的治疗获益情况。
Cancer. 2015 Apr 15;121(8):1328-38. doi: 10.1002/cncr.29208. Epub 2014 Dec 19.
引用本文的文献
1
Retrospective analysis of 1539 nasopharyngeal carcinoma cases: chemotherapy should not be excluded for non-Asian patients with T1-2N1M0 stage.对1539例鼻咽癌病例的回顾性分析：对于T1-2N1M0期的非亚洲患者，不应排除化疗。
Front Oncol. 2025 Jan 17;14:1529136. doi: 10.3389/fonc.2024.1529136. eCollection 2024.
2
The use of adjuvant chemotherapy combined with concurrent chemoradiotherapy enhances survival rates in cases of locally advanced nasopharyngeal carcinoma.辅助化疗联合同步放化疗的应用可提高局部晚期鼻咽癌患者的生存率。
Am J Cancer Res. 2024 Jun 15;14(6):3142-3152. doi: 10.62347/WMLA4979. eCollection 2024.
3
Identification of markers for predicting prognosis and endocrine metabolism in nasopharyngeal carcinoma by miRNA-mRNA network mining and machine learning.通过 miRNA-mRNA 网络挖掘和机器学习鉴定预测鼻咽癌预后和内分泌代谢的标志物。
Front Endocrinol (Lausanne). 2023 Jul 19;14:1174911. doi: 10.3389/fendo.2023.1174911. eCollection 2023.
4
Roundabout Guidance Receptor 1 Is an Emerging Prognostic Biomarker for Nasopharyngeal Carcinoma.环指蛋白1是鼻咽癌一种新出现的预后生物标志物。
Clin Med Insights Oncol. 2022 Jul 22;16:11795549221113244. doi: 10.1177/11795549221113244. eCollection 2022.
5
Survival Effects of Radiotherapy on Patients Newly Diagnosed with Distant Metastatic Nasopharyngeal Carcinoma in Non-High-Incidence Areas.非高发地区初诊远处转移鼻咽癌患者放疗的生存效果
Cancer Manag Res. 2021 Nov 2;13:8169-8178. doi: 10.2147/CMAR.S334958. eCollection 2021.
6
The Stromal and Immune Landscape of Nasopharyngeal Carcinoma and Its Implications for Precision Medicine Targeting the Tumor Microenvironment.鼻咽癌的基质和免疫格局及其对靶向肿瘤微环境的精准医学的意义。
Front Oncol. 2021 Sep 10;11:744889. doi: 10.3389/fonc.2021.744889. eCollection 2021.
7
Influence of CDK5 Regulatory Subunit-Associated Protein 1-Like 1 Expression on the Survival of Patients with Non-Metastatic Nasopharyngeal Carcinoma.细胞周期蛋白依赖性激酶5调节亚基相关蛋白1样蛋白1表达对非转移性鼻咽癌患者生存的影响
Cancer Manag Res. 2021 Jun 17;13:4821-4828. doi: 10.2147/CMAR.S314925. eCollection 2021.
8
The Overexpression of NMHC IIA Promoted Invasion and Metastasis of Nasopharyngeal Carcinoma Cells.非肌肉型肌球蛋白重链IIA（NMHC IIA）的过表达促进了鼻咽癌细胞的侵袭和转移。
J Cancer. 2021 May 17;12(14):4218-4228. doi: 10.7150/jca.47506. eCollection 2021.
9
Association Between Vitamin D Exposure and Head and Neck Cancer: A Systematic Review With Meta-Analysis.维生素D暴露与头颈癌之间的关联：一项Meta分析的系统评价
Front Immunol. 2021 Feb 23;12:627226. doi: 10.3389/fimmu.2021.627226. eCollection 2021.
10
Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma.鼻咽癌中 EB 病毒 DNA 及其他液体活检标志物的临床实用性。
Cancer Commun (Lond). 2020 Nov;40(11):564-585. doi: 10.1002/cac2.12100. Epub 2020 Sep 28.
本文引用的文献
1
The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis.调强放疗时代 II 期鼻咽癌同期化疗的作用：系统评价和荟萃分析。
PLoS One. 2018 Mar 22;13(3):e0194733. doi: 10.1371/journal.pone.0194733. eCollection 2018.
2
Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.同期放化疗治疗局部晚期鼻咽癌的诱导化疗：系统评价和荟萃分析。
Radiother Oncol. 2018 Oct;129(1):10-17. doi: 10.1016/j.radonc.2018.02.027. Epub 2018 Mar 16.
3
A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02).诱导多西紫杉醇-顺铂-5FU 序贯同期顺铂-RT 与同期顺铂-RT 治疗鼻咽癌的随机试验（GORTEC 2006-02）。
Ann Oncol. 2018 Mar 1;29(3):731-736. doi: 10.1093/annonc/mdx770.
4
Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial.局部区域晚期鼻咽癌患者的辅助化疗：一项3期多中心随机对照试验的长期结果
Eur J Cancer. 2017 Apr;75:150-158. doi: 10.1016/j.ejca.2017.01.002. Epub 2017 Feb 22.
5
Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.新辅助化疗后序贯同步放化疗与单纯同步放化疗治疗局部晚期鼻咽癌的III期多中心随机对照试验
Eur J Cancer. 2017 Apr;75:14-23. doi: 10.1016/j.ejca.2016.12.039. Epub 2017 Feb 16.
6
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.诱导化疗加同期放化疗对比单纯同期放化疗治疗局部晚期鼻咽癌：一项 3 期、多中心、随机对照临床试验。
Lancet Oncol. 2016 Nov;17(11):1509-1520. doi: 10.1016/S1470-2045(16)30410-7. Epub 2016 Sep 27.
7
Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis.鼻咽癌的化学治疗与放射治疗：MAC-NPC 荟萃分析更新。
Lancet Oncol. 2015 Jun;16(6):645-55. doi: 10.1016/S1470-2045(15)70126-9. Epub 2015 May 6.
8
Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.血浆 Epstein-Barr 病毒 DNA 和 ERCC1 单核苷酸多态性在鼻咽癌中的临床应用。
Cancer. 2015 Aug 15;121(16):2720-9. doi: 10.1002/cncr.29413. Epub 2015 May 6.
9
Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.同步放化疗联合或不联合诱导性吉西他滨、卡铂和紫杉醇：一项针对局部晚期鼻咽癌的随机2/3期试验。
Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):952-60. doi: 10.1016/j.ijrobp.2015.01.002.
10
Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma.NPC-0501试验的初步结果，该试验评估了局部晚期鼻咽癌患者从同步辅助放化疗改为诱导-同步放化疗、从氟尿嘧啶改为卡培他滨以及从常规放疗分割改为加速放疗分割后的治疗获益情况。
Cancer. 2015 Apr 15;121(8):1328-38. doi: 10.1002/cncr.29208. Epub 2014 Dec 19.
Zotero 插件